-
Septodont Parcan Sodium Hypochlorite Solution
Ready to use solution, specially formulated for use in endodontics.
Buffered and stabilized formulation, that maintains the solution properties throughout its shelf life.
Facilitates reaming through dissolution of the organic content of the root canal system.
Wide bactericidal spectrum, including the majority of endodontics pathogens.US$25.00US$30.00Septodont Parcan Sodium Hypochlorite Solution
US$25.00US$30.00 -
Septodont Canal +
- Lubricating and water-soluble gel.
- Clings to instruments and facilitates mechanical preparation.
- Makes mechanical reaming easier and faster as EDTA chelates mineral components of dentin.
US$29.00US$36.00Septodont Canal +
US$29.00US$36.00
septodont
Septodont, a French pharmaceutical and medical device company, has established itself as a leading developer, manufacturer, and distributor of dental consumables. With headquarters in Saint-Maur-des Fossés, France, Septodont has been at the forefront of the dental industry since its inception in 1932. The company has introduced renowned brands such as Endomethasone, Alvogyl, and Detartrine, solidifying its global presence. Septodont has emerged as a frontrunner in dental anesthesia, revolutionizing the field with its expertise and groundbreaking products. The company acquired a dedicated dental needle manufacturing site in France in 1990, positioning itself as a leader in anesthesia. In 2000, Septodont introduced Septocaine, the first articaine-based anesthetic, in the United States, further cementing its pioneering status. The acquisition of Novocol, a Canadian injectable anesthetic facility, further enhanced Septodont’s capabilities in anesthesia. Committed to pushing boundaries in dental therapeutics, Septodont has invested in extensive research and development. This dedication has led to the introduction of Biodentine and Bioroot RCS, two innovative products based on ABS Technology (Active Biosilicate Technology). These bioactive and biocompatible therapeutic solutions offer advanced treatment options to dental professionals, elevating patient care and outcomes. Septodont’s global expansion strategy has included strategic acquisitions to broaden its product portfolio and reach. In 2014, the company acquired TDV, a Brazilian company specializing in restorative materials, followed by the acquisition of DLA in 2016, expanding its presence in the Brazilian market for injectable anesthetics. Additionally, Septodont acquired Duoject in 2015, a Canadian company focused on the design of injection devices. To further strengthen its manufacturing capabilities, Septodont inaugurated a new unit for injectable anesthetics at its headquarters in Saint-Maur-des-Fossés, France, in 2016. Dental professionals worldwide rely on Septodont’s high-quality products and cutting-edge solutions to deliver optimal patient care. Through its unwavering dedication to research, development, and strategic acquisitions, Septodont remains at the forefront of the dental industry, driving advancements and enhancing the practice of dentistry.